Protein / target

Tumor-associated calcium signal transducer 2

Encoded byTACSTD2P09758Homo sapiensSwiss-Prot

UniProt: P09758 Ensembl: ENSG00000184292 HGNC: HGNC:11530 NCBI Gene: 4070

Clinically validated

Therapeutic maturity

Approved medicines

Open Targets target-level

View by indication →

Clinical trials

Antibody-tractable

Druggability

UniProt SigP or TMHMM

Protein at a glance

Biological role

Negative regulation of epithelial cell migration

Strongest disease association

Gelatinous drop-like corneal dystrophy

Via encoding gene TACSTD2 · Genetic evidence · score 0.82

Therapeutic position

Established drug target

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

May function as a growth factor receptor

Subcellular location

Membrane

Domains and Gene Ontology detail (19)

Domains & features

Thyroglobulin type-1

Gene Ontology

Cbasal plasma membrane
Ccytosol
Cextracellular exosome
Cextracellular space
Clateral plasma membrane
Cmembrane
Cnucleus
Cplasma membrane
Pnegative regulation of branching involved in ureteric bud morphogenesis
Pnegative regulation of cell motility
Pnegative regulation of epithelial cell migration
Pnegative regulation of ruffle assembly

323 aa · 36 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGO

View supporting evidence

Cell migration

·negative regulation of cell motility
·negative regulation of epithelial cell migration

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

1 medicine · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Breast Neoplasms1 medicine

sacituzumab govitecan

Triple Negative Breast Neoplasms1 medicine

sacituzumab govitecan

Broader indication categories (1)

Neoplasms1 medicine

sacituzumab govitecan

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

2 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

sacituzumab govitecan

Narrow target profileApprovedBinding agent

Tumor-associated calcium signal transducer 2 binding agent

Indicated for Breast Neoplasms, Triple Negative Breast Neoplasms, Neoplasms

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

datopotamab deruxtecan

Narrow target profileApprovedBinding agent

Tumor-associated calcium signal transducer 2 binding agent

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TACSTD2

Gene-level evidence surfaced through the gene TACSTD2that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Gelatinous drop-like corneal dystrophy

0.83Well supported

Genetic evidence dominant · Open Targets 0.73

Breast Neoplasms

0.76Well supported

Clinical evidence dominant · Open Targets 0.61

Carcinoma, Non-Small-Cell Lung

0.69Moderately supported

Clinical evidence dominant · Open Targets 0.55

Triple Negative Breast Neoplasms

0.68Moderately supported

Clinical evidence dominant · Open Targets 0.55

Neoplasms

0.65Moderately supported

Clinical evidence dominant · Open Targets 0.51

View evidence synthesis (5)

Gelatinous drop-like corneal dystrophyWell supported

0.83

agreement 0.69–0.97

Genetic94%Literature6%Genetic literaturedup

Open Targets aggregate 0.73 · 2 independent evidence families · 1 not counted as duplicate

Breast NeoplasmsWell supported

0.76

agreement 0.60–0.91

Clinical83%Literature17%

Open Targets aggregate 0.61 · 2 independent evidence families

Carcinoma, Non-Small-Cell LungModerately supported

0.69

agreement 0.54–0.84

Clinical84%Literature17%

Open Targets aggregate 0.55 · 2 independent evidence families

Triple Negative Breast NeoplasmsModerately supported

0.68

agreement 0.53–0.84

Clinical96%Literature5%

Open Targets aggregate 0.55 · 2 independent evidence families

NeoplasmsModerately supported

0.65

agreement 0.49–0.80

Clinical80%Literature20%

Open Targets aggregate 0.51 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Gelatinous drop-like corneal dystrophy0.73

Breast Neoplasms0.61

Triple Negative Breast Neoplasms0.55

Carcinoma, Non-Small-Cell Lung0.55

Neoplasms0.51

Urothelial carcinoma0.44

Cartilage Diseases0.32

Small Cell Lung Carcinoma0.31

Drug development

2 compounds recorded · 2 approved

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 2 drugs that target this protein in Forefront's canonical graph (1 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (2)

SACITUZUMAB GOVITECANApproval

DATOPOTAMAB DERUXTECANApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot sigp or tmhmm and go cc med conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (database ubiquitination) — no clinical-stage drug of this modality recorded.

Other modalities — Strong

Approved Drug support this modality.

View underlying tractability evidence (5)

AB · UniProt SigP or TMHMMAB · GO CC med confAB · Human Protein Atlas locPR · Database UbiquitinationOC · Approved Drug

Raw Open Targets tractability assessment buckets, by modality.

Clinical trials

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH)PHASE4

RECRUITING · via datopotamab deruxtecan · NCT07357597

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerPHASE3

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07178730

A Randomized, Open-label, Multicenter, Phase 3 Study of YL202 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of ChemotherapyPHASE3

RECRUITING · via sacituzumab govitecan · NCT07461454

A Phase III Randomized Trial of Pembrolizumab in Combination With Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial CancerPHASE3

RECRUITING · via sacituzumab govitecan · NCT06524544

View all trials (26)

A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)PHASE3

RECRUITING · via datopotamab deruxtecan · NCT07291037

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)PHASE3

RECRUITING · via sacituzumab govitecan · NCT06801834

A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIANPHASE3

RECRUITING · via sacituzumab govitecan · NCT06431633

A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT06564844

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan Versus Sacituzumab Govitecan+Pembrolizumab in Low-risk, Triple-negative Early Breast Cancer (ADAPT-TN-III)PHASE3

RECRUITING · via sacituzumab govitecan · NCT06081244

A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung CancerPHASE3

RECRUITING · via datopotamab deruxtecan · NCT06350097

A Randomized, Open Label, Multicenter Phase II/III Trial of Sacituzumab Govitecan Compared to Standard of Care in Metastatic, Refractory Colorectal Cancer PatientsPHASE2/PHASE3

RECRUITING · via sacituzumab govitecan · NCT06243393

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)PHASE3

RECRUITING · via datopotamab deruxtecan · NCT06357533

ISIdE: Open Label, Multicentric, Single-arm Phase IIIB Trial to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Triple Negative Metastatic Breast Cancer Patients With a Biomarker AnalysisPHASE3

RECRUITING · via sacituzumab govitecan · NCT05552001

An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)PHASE3

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT05609968

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05555732

A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05687266

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)PHASE3

ACTIVE_NOT_RECRUITING · via datopotamab deruxtecan · NCT05215340

A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 TherapyPHASE3

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04579224

Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIAPHASE3

ACTIVE_NOT_RECRUITING · via sacituzumab govitecan · NCT04595565

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor TherapyPHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07504588

A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants With Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)PHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07393555

Phase II Study to Improve Sacituzumab Govitecan Tolerance With Atropine in Patients With Advanced Triple-Negative and Hormone Receptor-Positive/HER2-Negative Breast CancerPHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07367178

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPHASE2

RECRUITING · via sacituzumab govitecan · NCT07339059

A Single-Arm, Phase II Prospective Study Of Lucanoximab Combined With Tagolimab As Neoadjuvant Therapy For Resectable Head And Neck Squamous Cell CarcinomaPHASE2

RECRUITING · via sacituzumab govitecan · NCT07492914

PREDICT-RD: Postoperative Molecular Residual Disease by ctDNA Surveillance in TNBC With Residual DiseasePHASE2

RECRUITING · via datopotamab deruxtecan · NCT07069595

Sequencing Sacituzumab Govitecan vs. Trastuzumab Deruxtecan in HER2-LOw/TROP2-High Metastatic Breast Cancer: A Randomized Phase II StudyPHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07368543

A Phase I/II Clinical Study of Sacituzumab Govitecan Combined With Intrathecal Chemotherapy for the Treatment of Leptomeningeal Metastases From Her2-negative Breast CancerPHASE1/PHASE2

RECRUITING · via sacituzumab govitecan · NCT06462092

Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast CancerPHASE1/PHASE2

RECRUITING · via sacituzumab govitecan · NCT06963905

A Phase II Study of First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.PHASE2

NOT_YET_RECRUITING · via sacituzumab govitecan · NCT07299409

An Open-label Randomised, Phase II Trial of Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerPHASE2

RECRUITING · via datopotamab deruxtecan · NCT06954480

ClinicalTrials.gov via the drug-target graph.

What's happening now

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 2 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

Trial status changed2026-07-21
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Status changed to Completed · ClinicalTrials.gov · via sacituzumab govitecan
Indication expanded2026-06-24
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
Indication expanded2026-06-24
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
New publication2026-01-01
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
The New England journal of medicine · 2026 · 3 citations · Europe PMC · via sacituzumab govitecan
Regulatory approval2025-04-04
Approval: Datroway (EMA)
ema · regulatory · ema · via datopotamab deruxtecan
Label change2025-03-26
Label change: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
Indication expanded2024-11-22
Indication expansion: SACITUZUMAB GOVITECAN (BLA761115)
fda · regulatory · fda · via sacituzumab govitecan
New publication2024-10-01
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
Nature medicine · 2024 · 32 citations · Europe PMC · via sacituzumab govitecan
New publication2024-07-31
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 37 citations · Europe PMC · via sacituzumab govitecan
New publication2024-05-31
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 97 citations · Europe PMC · via sacituzumab govitecan
New publication2024-04-05
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
Clinical pharmacokinetics · 2024 · 19 citations · Europe PMC · via sacituzumab govitecan
New publication2024-01-23
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 66 citations · Europe PMC · via sacituzumab govitecan

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.